Australia, Oct. 28 -- Bristol-Myers Squibb Co., owns the trademark (2573783) for 'FYMILSI' till Aug. 5, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; stem cells for medical purposes; diagnostic radiopharmaceutical preparations; diagnostic preparations for medical purposes; radiopharmaceutical preparations for the treatment of cancer and immune system related diseases and disorders.] and 5 [All items in this class ...